Email
IZ Express #1,696: FDA licenses second RSV vaccine for older adults, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,696: FDA licenses second RSV vaccine for older adults, and more |
| Date | June 7, 2023 10:01 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed] [link removed] [link removed] [link removed] [link removed]
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,696: June 7, 2023
Top Stories
* FDA licenses second respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for use at its June meeting (#IZX1)
* "Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022" published in MMWR (#IZX2)
* Check out our latest Ask the Experts video on Facebook, LinkedIn, Twitter, YouTube, and Instagram. Follow us and share our posts featuring Ask the Experts and our clinical resources. (#IZX3)
* Floods, hurricanes, tornadoes, disasters: it’s the season to exercise your emergency plan (#IZX4)
* Spotlight: Immunize.org resources that focus on vaccine products and manufacturers (#IZX5)
* Journalists interview Immunize.org experts (#IZX6)
* Vaccines in the news (#IZX7)
Immunize.org Pages and Handouts
* Recap: Immunize.org updated these clinic resources in April and May (#IZX8)
Vaccine Information Statements
* Recap: Two new interim Vaccine Information Statements released in May (#IZX9)
Featured Resources
* AAP offers new podcast episode from Pediatrics on Call discussing vaccine hesitancy (#IZX10)
* Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations (#IZX11)
* Laminated versions of CDC’s 2023 immunization schedules are going fast. Get yours before they're gone! (#IZX12)
Notable Publications
* “Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink” published in Pediatrics (#IZX13)
* "Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth" published in Pediatrics (#IZX14)
* "Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020" published in Pediatrics (#IZX15)
Upcoming Events
* Virtual: Moderna offers five-part webinar series High-Risk Populations – Protecting Patients at High Risk of Severe COVID-19 in June (#IZX16)
* Virtual: Watch June 15–16 National Vaccine Advisory Committee meeting (#IZX17)
* Virtual: Watch June 21–23 ACIP meeting. Topics include RSV, polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines. (#IZX18)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
FDA licenses second respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for use at its June meeting
According to CDC ([link removed]) , each year in the United States respiratory syncytial virus (RSV) leads to 60,000–120,000 hospitalizations and 6,000–10,000 deaths among adults age 65 years and older. Like influenza, RSV is a seasonal virus, with peak activity typically occurring each fall or winter.
On May 31, FDA licensed the second vaccine to prevent RSV in adults, known as Abrysvo (uh-BREEZ-voh) and manufactured by Pfizer. Abrysvo is licensed for preventing lower respiratory tract disease (LRTD) caused by RSV in people age 60 years and older. The next step is for Advisory Committee on Immunization Practices (ACIP) to consider recommendations for the vaccine's use at its June meeting. A portion of the FDA announcement ([link removed]) appears below.
In an ongoing clinical trial, approximately 17,000 individuals have received Abrysvo and approximately 17,000 individuals have received a placebo. Data from the first RSV season of the study were available for the FDA’s analysis. Abrysvo reduced the risk of developing RSV-associated LRTD with two or more symptoms by 66.7% and with three or more symptoms by 85.7%. Among a subset of clinical trial participants, the most commonly reported side effects were fatigue, headache, pain at the injection site and muscle pain. Guillain-Barré syndrome was reported 7 days after receipt of Abrysvo in one participant and Miller Fisher syndrome (a variant form of Guillain-Barré syndrome), was reported 8 days after receipt of Abrysvo in one participant. Atrial fibrillation within 30 days after vaccination was reported in 10 participants who received Abrysvo and 4 participants who received placebo.
[link removed]
Related Links
* FDA: Roundup ([link removed]) (6/2/23)
* FDA: Abrysvo product approval letter ([link removed]) (5/31/23)
* FDA: Abrysvo ([link removed]) web page
* FDA: Abrysvo Package Insert ([link removed])
* Immunize.org's IZ Express newsletter: FDA approves first respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for its use in future meetings ([link removed]) (5/10/23)
Back to top (#Top)
------------------------------------------------------------
"Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022" published in MMWR
CDC published Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022 ([link removed]) on June 2 in MMWR. A portion of the summary appears below.
SARS-CoV-2 hybrid immunity (immunity derived from both previous infection and vaccination) has been reported to provide better protection than that from infection or vaccination alone. . . .
By the third quarter of 2022, an estimated 96.4% of persons aged ≥16 years in a longitudinal blood donor cohort had SARS-CoV-2 antibodies from previous infection or vaccination, including 22.6% from infection alone and 26.1% from vaccination alone; 47.7% had hybrid immunity. Hybrid immunity prevalence was lowest among adults aged ≥65 years. . . .
Low prevalence of infection-induced and hybrid immunity among older adults, who are at increased risk for severe disease if infected, reflects the success of public health infection prevention efforts while also highlighting the importance of this group staying up to date with recommended COVID-19 vaccination, including at least 1 bivalent dose.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
[link removed]
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
Back to top (#Top)
------------------------------------------------------------
Check out our latest Ask the Experts video on Facebook, LinkedIn, Twitter, YouTube, and Instagram. Follow us and share our posts featuring Ask the Experts and our clinical resources.
Immunize.org's social media program highlights our educational resources for a new audience of vaccinators. Our latest short video, “Can COVID-19 Vaccination Lead to Fertility Problems?” is available now on our YouTube channel ([link removed]) , along with all of our Ask the Experts videos. Our social media channels now feature our most popular printable resources and Ask the Experts questions and answers, as well as announcements important to frontline vaccinators.
[link removed]
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at Immunize.org ([link removed])
* Twitter at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
Floods, hurricanes, tornadoes, disasters: it’s the season to exercise your emergency plan
Power outages can create emergency conditions that damage your valuable vaccine inventory. For this reason, every site that stocks vaccines needs an emergency plan. Every Vaccines for Children (VFC) site is required to have one. Follow CDC’s Vaccine Storage and Handling Toolkit ([link removed]) to create an emergency plan for your clinic and then practice your plan this month. Build redundancy, flexibility, and communication into your plan. Consider:
* Equipment backup options
* Alternate storage options
* Vaccine transport plans
Your plan should include at least one facility that is willing to receive and properly store your vaccine inventory if it must be relocated. CDC’s guide provides detailed instructions on monitoring temperatures during a power outage and what to do once proper storage is restored. Print out your plan before the power goes out!
Prevent avoidable vaccine waste by training your staff on emergency procedures, including after-hours roles and responsibilities. Then run an exercise to check understanding.
Related Links
* CDC: Vaccine Storage and Handling Toolkit ([link removed]) (70 pages, January 2023)
* CDC: Packing Vaccines for Transport during Emergencies ([link removed]) (Aug 2015)
* Immunize.org: Clinic Tools: Storage and Handling ([link removed]) main page
* Immunize.org: Emergency Response Worksheet ([link removed]) (PDF)
* HHS: Technical Resources: Utility Failures ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org resources that focus on vaccine products and manufacturers
In this week's Spotlight, we summarize resources at Immunize.org that focus on specific vaccine products.
Package Inserts and FDA Product Approvals ([link removed]) main page provides up-to-date product information links and links to FDA vaccine approval web pages for all vaccines licensed for use in the United States.
Vaccine Manufacturers ([link removed]) main page provides links to the websites of the vaccine manufacturers in the United States, as well as providing contact information such as telephone numbers and email addresses. In addition, the vaccine products for each of the companies are listed.
Vaccines ([link removed]) main page links to information about 24 vaccines and the diseases they prevent. For each vaccine, access the latest recommendations, information, and resources from Immunize.org and CDC.
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is one of our recent citations.
* Wall Street Journal: New Pfizer Vaccine Rolls Out into Headwinds of Hesitancy ([link removed] ) (5/31/23)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* The Atlantic: What the Pandemic Simulations Missed ([link removed]) (5/30/23)
* New York Times: With Mpox at Risk of Flaring, Health Officials Advise, ‘Get Vaccinated’ ([link removed]) (5/29/23)
* Washington Post: Military Members Half as Likely as Civilians to Receive HPV Vaccine ([link removed]) ([link removed]) (5/28/23)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Recap: Immunize.org updated these clinic resources in April and May
IZ Express regularly summarizes Immunize.org’s new and updated educational materials. All Immunize.org materials are free to distribute. In recent weeks, Immunize.org updated these helpful materials:
Immunize.org Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (05/29/23)
* Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Standing Orders for Administering:
+ Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
+ Measles, Mumps, and Rubella Vaccine to Children and Teens ([link removed])
+ Measles, Mumps, and Rubella Vaccine to Adults ([link removed])
+ Hepatitis A Vaccine to Children and Teens ([link removed])
+ Inactivated Poliovirus Vaccine to Infants and Children ([link removed])
+ Varicella Vaccine to Children and Teens ([link removed])
+ Varicella Vaccine to Adults ([link removed])
* Medical Management of Vaccine Reactions in Children and Teens in a Community Setting ([link removed])
* Medical Management of Vaccine Reactions in Adults in a Community Setting ([link removed])
* How to Administer:
+ Intramuscular and Subcutaneous Vaccine Injections ([link removed])
+ Intramuscular and Subcutaneous Vaccine Injections to Adults ([link removed])
* Administering Vaccines: Dose, Route, Site, and Needle Size ([link removed])
* Administering Vaccines to Adults: Dose, Route, Site, and Needle Size ([link removed])
* Other
+ Meningococcal B Vaccine Recommendations by Age and Risk Factor ([link removed])
+ Don’t Be Guilty of These Preventable Errors in Vaccine Storage and Handling! ([link removed])
+ Supplies You May Need at an Immunization Clinic ([link removed])
+ Suggestions to Improve Your Immunization Services ([link removed])
+ Record of Vaccine Declination ([link removed])
Immunize.org Web Pages
* Vaccines: COVID-19 ([link removed])
* Vaccine Timeline ([link removed])
* Ask the Experts:
+ Rabies ([link removed])
+ Varicella ([link removed])
+ Vaccine Recommendations ([link removed])
* Talking about Vaccines:
+ Religious Concerns ([link removed])
+ Responding to Parents ([link removed])
Immunize.org Printable Materials for Patients
* Top 10 Reasons to Protect Your Child by Vaccinating ([link removed])
* After the Shots . . . What to Do If Your Child has Discomfort ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) (corrected), French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Questions Parents Ask About Vaccinations for Babies ([link removed])
* Vaccinations for Preteens and Teens ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Vaccinations for Adults ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Tips for Locating Old Immunization Records ([link removed])
* Pneumococcus: Questions and Answers ([link removed])
* Protect Yourself from Hepatitis A and Hepatitis B ([link removed]) with translation in Spanish ([link removed])
* Shingles (Zoster): Questions and Answers ([link removed])
* MMR Vaccine Does Not Cause Autism ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,200 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its eight subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
Back to top (#Top)
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: Two new interim Vaccine Information Statements released in May
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
On May 12, CDC released two new interim VISs:
* Hepatitis B ([link removed])
* Pneumococcal conjugate (PCV) ([link removed])
In response, Immunize.org updated two handouts related to VISs:
* Dates of Current Vaccine Information Statements (VISs) ([link removed])
* You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law! ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
AAP offers new podcast episode from Pediatrics on Call discussing vaccine hesitancy
American Academy of Pediatrics (AAP) posted a new entry in its Pediatrics On Call podcast series: Drowning Prevention, Vaccine Hesitancy ([link removed]) (33 minutes). A description from the podcast web page appears below.
In the first full episode, hosts Joanna Parga-Belinkie, MD, FAAP and David Hill, MD, FAAP share why they became pediatricians and introduce listeners to the new podcast from the American Academy of Pediatrics. Guest interviews address two of the biggest issues facing children’s health today: drowning and vaccine hesitancy.
[link removed]
Related Link
* Pediatrics On Call podcast page ([link removed])
Back to top (#Top)
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the update Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: 2020 ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13–17 Years — United States, 2020 ([link removed])
* CDC: Adolescent Vaccination Coverage in the U.S. ([link removed])
Back to top (#Top)
------------------------------------------------------------
Laminated versions of CDC’s 2023 immunization schedules are going fast. Get yours before they're gone!
Immunize.org's laminated versions of the 2023 U.S. child and adolescent immunization schedule ([link removed]) and the 2023 U.S. adult immunization schedule ([link removed]) are still available. Order while supplies last. Once sold out, we will not print more until 2024.
While the schedules are available online from CDC at no cost, Immunize.org’s laminated schedules are ideal for use in any busy healthcare setting. Their tough coating can be wiped down, and they’re durable enough to stand up to a year of use.
* Length: Each schedule with appendices is 12 pages
* Size: Standard 8.5” X 11” booklet format
* Full Color: With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes
* Bonus: The adult schedule includes Immunize.org’s popular 1-page handout summarizing the dose, route, and needle length recommendations for all vaccines and recipients
[link removed] [link removed]
Pricing for Each Schedule
$10.00: 1 copy
$ 9.50 each: 2–4 copies
$ 8.50 each: 5–19 copies
$ 7.50 each: 20–99 copies
$ 6.00 each: 100–499 copies
$ 5.00 each: 500–999 copies
$ 4.00 each: 1,000–1,999 copies
$ 3.25 each: 2,000+ copies
Visit Shop Immunize.org: Laminated Schedules ([link removed]) to view images of each page and order today!
For additional information, call 651-647-9009 or email [email protected] (mailto:[email protected]) .
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
* CDC: Immunization Schedules ([link removed])
Back to top (#Top)
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink” published in Pediatrics
In the June 6 issue, Pediatrics published Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink ([link removed]) . The media summary appears below.
Researchers reviewed more than 245,000 COVID-19 mRNA vaccine doses (135,005 doses of Pfizer-BioNTech COVID-19 vaccine to children 4 years and younger and 112,006 doses of Moderna COVID-19 vaccine to children 5 years and younger) given over nine months and found no cause for concern during the 21 days after vaccination. Notably, the study did not identify any cases of myocarditis or pericarditis following any dose of vaccine [in these young children]. While one case of hemorrhagic stroke and one case of pulmonary embolism were identified after vaccination, chart review found each outcome was unrelated to vaccination as both children had congenital abnormalities. In descriptive analyses, one case of anaphylaxis was found also to be unrelated to vaccination (due to food allergy). Authors of the study expressed confidence in the findings based on the diverse population surveyed, weekly analyses, and a robust capture of outcome and vaccination data. They say the results should provide
reassurance to clinicians, parents, and policymakers.
Related Link
* JAMA Pediatrics: Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years ([link removed]) (5/22/23)
Back to top (#Top)
------------------------------------------------------------
"Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth" published in Pediatrics
In the May 5 issue, Pediatrics published Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth ([link removed]) . The conclusions section appears below.
Messages that focus on trusted parents choosing to vaccinate their children were more effective at promoting parents’ COVID-19 vaccination intentions for their children than alternative messages. These findings have implications for public health messaging and pediatric providers’ communications with parents.
Back to top (#Top)
------------------------------------------------------------
"Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020" published in Pediatrics
In the May 23 issue, Pediatrics published Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020 ([link removed]) . The conclusions section appears below.
Parents who cited vaccine safety as a reason for not intending to vaccinate their adolescent children against HPV increased over time. Findings support efforts to address parental safety concerns surrounding HPV vaccination.
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Moderna offers five-part webinar series High-Risk Populations – Protecting Patients at High Risk of Severe COVID-19 in June
Moderna is offering a free, five-part webinar series High-Risk Populations – Protecting Patients at High-Risk of Severe COVID-19 ([link removed]) in June. This five-part webinar series will discuss the continued risks and consequences of COVID-19 infections in high-risk populations. Each event will focus on a different high-risk population. Courses include:
* TODAY: June 7 at 3:00 p.m. (ET): "Older Adults (65+)"
* June 13 at 1:00 p.m. (ET): "Patients with Chronic Diseases"
* June 15 at 1:00 p.m. (ET): "Immunocompromised Patients"
* June 22 at 1:00 p.m. (ET): "Patients with Cardiovascular Diseases"
* June 28 at 1:30 p.m. (ET): "Patients with Respiratory Diseases"
[link removed]
Registration is required for each event separately.
Register for the free webinars ([link removed]) .
Back to top (#Top)
------------------------------------------------------------
Virtual: Watch June 15–16 National Vaccine Advisory Committee meeting
The National Vaccine Advisory Committee (NVAC) will hold its next meeting June 15–16, starting at 9 a.m. (ET). NVAC will hear presentations on vaccine safety, antimicrobial resistance, pandemic preparedness, and routine vaccination.
Attendance is open to the public on a first-come, first-served basis by registration. Registration is now available online ([link removed]) .
Related Link
* NVAC: ([link removed]) Meeting Information ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Virtual: Watch June 21–23 ACIP meeting. Topics include RSV, polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines.
CDC will convene an extended, 3-day meeting of the Advisory Committee on Immunization Practices ([link removed]) (ACIP), June 21–23, starting at 8 a.m. (ET). ACIP will discuss vaccination recommendations for respiratory syncytial virus (RSV), polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines.
[link removed]
No registration is required to watch webcasts of live ACIP meetings or listen via telephone. Opportunities for public comment are described on the website.
View the agenda ([link removed]) .
Related Links
* ACIP main page ([link removed]) for access to webcast, agendas
* ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,696: June 7, 2023
Top Stories
* FDA licenses second respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for use at its June meeting (#IZX1)
* "Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022" published in MMWR (#IZX2)
* Check out our latest Ask the Experts video on Facebook, LinkedIn, Twitter, YouTube, and Instagram. Follow us and share our posts featuring Ask the Experts and our clinical resources. (#IZX3)
* Floods, hurricanes, tornadoes, disasters: it’s the season to exercise your emergency plan (#IZX4)
* Spotlight: Immunize.org resources that focus on vaccine products and manufacturers (#IZX5)
* Journalists interview Immunize.org experts (#IZX6)
* Vaccines in the news (#IZX7)
Immunize.org Pages and Handouts
* Recap: Immunize.org updated these clinic resources in April and May (#IZX8)
Vaccine Information Statements
* Recap: Two new interim Vaccine Information Statements released in May (#IZX9)
Featured Resources
* AAP offers new podcast episode from Pediatrics on Call discussing vaccine hesitancy (#IZX10)
* Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations (#IZX11)
* Laminated versions of CDC’s 2023 immunization schedules are going fast. Get yours before they're gone! (#IZX12)
Notable Publications
* “Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink” published in Pediatrics (#IZX13)
* "Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth" published in Pediatrics (#IZX14)
* "Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020" published in Pediatrics (#IZX15)
Upcoming Events
* Virtual: Moderna offers five-part webinar series High-Risk Populations – Protecting Patients at High Risk of Severe COVID-19 in June (#IZX16)
* Virtual: Watch June 15–16 National Vaccine Advisory Committee meeting (#IZX17)
* Virtual: Watch June 21–23 ACIP meeting. Topics include RSV, polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines. (#IZX18)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
FDA licenses second respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for use at its June meeting
According to CDC ([link removed]) , each year in the United States respiratory syncytial virus (RSV) leads to 60,000–120,000 hospitalizations and 6,000–10,000 deaths among adults age 65 years and older. Like influenza, RSV is a seasonal virus, with peak activity typically occurring each fall or winter.
On May 31, FDA licensed the second vaccine to prevent RSV in adults, known as Abrysvo (uh-BREEZ-voh) and manufactured by Pfizer. Abrysvo is licensed for preventing lower respiratory tract disease (LRTD) caused by RSV in people age 60 years and older. The next step is for Advisory Committee on Immunization Practices (ACIP) to consider recommendations for the vaccine's use at its June meeting. A portion of the FDA announcement ([link removed]) appears below.
In an ongoing clinical trial, approximately 17,000 individuals have received Abrysvo and approximately 17,000 individuals have received a placebo. Data from the first RSV season of the study were available for the FDA’s analysis. Abrysvo reduced the risk of developing RSV-associated LRTD with two or more symptoms by 66.7% and with three or more symptoms by 85.7%. Among a subset of clinical trial participants, the most commonly reported side effects were fatigue, headache, pain at the injection site and muscle pain. Guillain-Barré syndrome was reported 7 days after receipt of Abrysvo in one participant and Miller Fisher syndrome (a variant form of Guillain-Barré syndrome), was reported 8 days after receipt of Abrysvo in one participant. Atrial fibrillation within 30 days after vaccination was reported in 10 participants who received Abrysvo and 4 participants who received placebo.
[link removed]
Related Links
* FDA: Roundup ([link removed]) (6/2/23)
* FDA: Abrysvo product approval letter ([link removed]) (5/31/23)
* FDA: Abrysvo ([link removed]) web page
* FDA: Abrysvo Package Insert ([link removed])
* Immunize.org's IZ Express newsletter: FDA approves first respiratory syncytial virus (RSV) vaccine for people age 60 and older; ACIP will consider recommendations for its use in future meetings ([link removed]) (5/10/23)
Back to top (#Top)
------------------------------------------------------------
"Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022" published in MMWR
CDC published Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections among Blood Donors, by COVID-19 Vaccination Status—United States, April 2021–September 2022 ([link removed]) on June 2 in MMWR. A portion of the summary appears below.
SARS-CoV-2 hybrid immunity (immunity derived from both previous infection and vaccination) has been reported to provide better protection than that from infection or vaccination alone. . . .
By the third quarter of 2022, an estimated 96.4% of persons aged ≥16 years in a longitudinal blood donor cohort had SARS-CoV-2 antibodies from previous infection or vaccination, including 22.6% from infection alone and 26.1% from vaccination alone; 47.7% had hybrid immunity. Hybrid immunity prevalence was lowest among adults aged ≥65 years. . . .
Low prevalence of infection-induced and hybrid immunity among older adults, who are at increased risk for severe disease if infected, reflects the success of public health infection prevention efforts while also highlighting the importance of this group staying up to date with recommended COVID-19 vaccination, including at least 1 bivalent dose.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
[link removed]
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
Back to top (#Top)
------------------------------------------------------------
Check out our latest Ask the Experts video on Facebook, LinkedIn, Twitter, YouTube, and Instagram. Follow us and share our posts featuring Ask the Experts and our clinical resources.
Immunize.org's social media program highlights our educational resources for a new audience of vaccinators. Our latest short video, “Can COVID-19 Vaccination Lead to Fertility Problems?” is available now on our YouTube channel ([link removed]) , along with all of our Ask the Experts videos. Our social media channels now feature our most popular printable resources and Ask the Experts questions and answers, as well as announcements important to frontline vaccinators.
[link removed]
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at Immunize.org ([link removed])
* Twitter at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
Floods, hurricanes, tornadoes, disasters: it’s the season to exercise your emergency plan
Power outages can create emergency conditions that damage your valuable vaccine inventory. For this reason, every site that stocks vaccines needs an emergency plan. Every Vaccines for Children (VFC) site is required to have one. Follow CDC’s Vaccine Storage and Handling Toolkit ([link removed]) to create an emergency plan for your clinic and then practice your plan this month. Build redundancy, flexibility, and communication into your plan. Consider:
* Equipment backup options
* Alternate storage options
* Vaccine transport plans
Your plan should include at least one facility that is willing to receive and properly store your vaccine inventory if it must be relocated. CDC’s guide provides detailed instructions on monitoring temperatures during a power outage and what to do once proper storage is restored. Print out your plan before the power goes out!
Prevent avoidable vaccine waste by training your staff on emergency procedures, including after-hours roles and responsibilities. Then run an exercise to check understanding.
Related Links
* CDC: Vaccine Storage and Handling Toolkit ([link removed]) (70 pages, January 2023)
* CDC: Packing Vaccines for Transport during Emergencies ([link removed]) (Aug 2015)
* Immunize.org: Clinic Tools: Storage and Handling ([link removed]) main page
* Immunize.org: Emergency Response Worksheet ([link removed]) (PDF)
* HHS: Technical Resources: Utility Failures ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org resources that focus on vaccine products and manufacturers
In this week's Spotlight, we summarize resources at Immunize.org that focus on specific vaccine products.
Package Inserts and FDA Product Approvals ([link removed]) main page provides up-to-date product information links and links to FDA vaccine approval web pages for all vaccines licensed for use in the United States.
Vaccine Manufacturers ([link removed]) main page provides links to the websites of the vaccine manufacturers in the United States, as well as providing contact information such as telephone numbers and email addresses. In addition, the vaccine products for each of the companies are listed.
Vaccines ([link removed]) main page links to information about 24 vaccines and the diseases they prevent. For each vaccine, access the latest recommendations, information, and resources from Immunize.org and CDC.
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is one of our recent citations.
* Wall Street Journal: New Pfizer Vaccine Rolls Out into Headwinds of Hesitancy ([link removed] ) (5/31/23)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* The Atlantic: What the Pandemic Simulations Missed ([link removed]) (5/30/23)
* New York Times: With Mpox at Risk of Flaring, Health Officials Advise, ‘Get Vaccinated’ ([link removed]) (5/29/23)
* Washington Post: Military Members Half as Likely as Civilians to Receive HPV Vaccine ([link removed]) ([link removed]) (5/28/23)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Recap: Immunize.org updated these clinic resources in April and May
IZ Express regularly summarizes Immunize.org’s new and updated educational materials. All Immunize.org materials are free to distribute. In recent weeks, Immunize.org updated these helpful materials:
Immunize.org Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (05/29/23)
* Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Standing Orders for Administering:
+ Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
+ Measles, Mumps, and Rubella Vaccine to Children and Teens ([link removed])
+ Measles, Mumps, and Rubella Vaccine to Adults ([link removed])
+ Hepatitis A Vaccine to Children and Teens ([link removed])
+ Inactivated Poliovirus Vaccine to Infants and Children ([link removed])
+ Varicella Vaccine to Children and Teens ([link removed])
+ Varicella Vaccine to Adults ([link removed])
* Medical Management of Vaccine Reactions in Children and Teens in a Community Setting ([link removed])
* Medical Management of Vaccine Reactions in Adults in a Community Setting ([link removed])
* How to Administer:
+ Intramuscular and Subcutaneous Vaccine Injections ([link removed])
+ Intramuscular and Subcutaneous Vaccine Injections to Adults ([link removed])
* Administering Vaccines: Dose, Route, Site, and Needle Size ([link removed])
* Administering Vaccines to Adults: Dose, Route, Site, and Needle Size ([link removed])
* Other
+ Meningococcal B Vaccine Recommendations by Age and Risk Factor ([link removed])
+ Don’t Be Guilty of These Preventable Errors in Vaccine Storage and Handling! ([link removed])
+ Supplies You May Need at an Immunization Clinic ([link removed])
+ Suggestions to Improve Your Immunization Services ([link removed])
+ Record of Vaccine Declination ([link removed])
Immunize.org Web Pages
* Vaccines: COVID-19 ([link removed])
* Vaccine Timeline ([link removed])
* Ask the Experts:
+ Rabies ([link removed])
+ Varicella ([link removed])
+ Vaccine Recommendations ([link removed])
* Talking about Vaccines:
+ Religious Concerns ([link removed])
+ Responding to Parents ([link removed])
Immunize.org Printable Materials for Patients
* Top 10 Reasons to Protect Your Child by Vaccinating ([link removed])
* After the Shots . . . What to Do If Your Child has Discomfort ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) (corrected), French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Questions Parents Ask About Vaccinations for Babies ([link removed])
* Vaccinations for Preteens and Teens ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Vaccinations for Adults ([link removed]) with translations inSpanish ([link removed]) , Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Vietnamese ([link removed])
* Tips for Locating Old Immunization Records ([link removed])
* Pneumococcus: Questions and Answers ([link removed])
* Protect Yourself from Hepatitis A and Hepatitis B ([link removed]) with translation in Spanish ([link removed])
* Shingles (Zoster): Questions and Answers ([link removed])
* MMR Vaccine Does Not Cause Autism ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,200 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its eight subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
Back to top (#Top)
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: Two new interim Vaccine Information Statements released in May
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
On May 12, CDC released two new interim VISs:
* Hepatitis B ([link removed])
* Pneumococcal conjugate (PCV) ([link removed])
In response, Immunize.org updated two handouts related to VISs:
* Dates of Current Vaccine Information Statements (VISs) ([link removed])
* You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law! ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
AAP offers new podcast episode from Pediatrics on Call discussing vaccine hesitancy
American Academy of Pediatrics (AAP) posted a new entry in its Pediatrics On Call podcast series: Drowning Prevention, Vaccine Hesitancy ([link removed]) (33 minutes). A description from the podcast web page appears below.
In the first full episode, hosts Joanna Parga-Belinkie, MD, FAAP and David Hill, MD, FAAP share why they became pediatricians and introduce listeners to the new podcast from the American Academy of Pediatrics. Guest interviews address two of the biggest issues facing children’s health today: drowning and vaccine hesitancy.
[link removed]
Related Link
* Pediatrics On Call podcast page ([link removed])
Back to top (#Top)
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the update Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: 2020 ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13–17 Years — United States, 2020 ([link removed])
* CDC: Adolescent Vaccination Coverage in the U.S. ([link removed])
Back to top (#Top)
------------------------------------------------------------
Laminated versions of CDC’s 2023 immunization schedules are going fast. Get yours before they're gone!
Immunize.org's laminated versions of the 2023 U.S. child and adolescent immunization schedule ([link removed]) and the 2023 U.S. adult immunization schedule ([link removed]) are still available. Order while supplies last. Once sold out, we will not print more until 2024.
While the schedules are available online from CDC at no cost, Immunize.org’s laminated schedules are ideal for use in any busy healthcare setting. Their tough coating can be wiped down, and they’re durable enough to stand up to a year of use.
* Length: Each schedule with appendices is 12 pages
* Size: Standard 8.5” X 11” booklet format
* Full Color: With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes
* Bonus: The adult schedule includes Immunize.org’s popular 1-page handout summarizing the dose, route, and needle length recommendations for all vaccines and recipients
[link removed] [link removed]
Pricing for Each Schedule
$10.00: 1 copy
$ 9.50 each: 2–4 copies
$ 8.50 each: 5–19 copies
$ 7.50 each: 20–99 copies
$ 6.00 each: 100–499 copies
$ 5.00 each: 500–999 copies
$ 4.00 each: 1,000–1,999 copies
$ 3.25 each: 2,000+ copies
Visit Shop Immunize.org: Laminated Schedules ([link removed]) to view images of each page and order today!
For additional information, call 651-647-9009 or email [email protected] (mailto:[email protected]) .
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
* CDC: Immunization Schedules ([link removed])
Back to top (#Top)
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink” published in Pediatrics
In the June 6 issue, Pediatrics published Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink ([link removed]) . The media summary appears below.
Researchers reviewed more than 245,000 COVID-19 mRNA vaccine doses (135,005 doses of Pfizer-BioNTech COVID-19 vaccine to children 4 years and younger and 112,006 doses of Moderna COVID-19 vaccine to children 5 years and younger) given over nine months and found no cause for concern during the 21 days after vaccination. Notably, the study did not identify any cases of myocarditis or pericarditis following any dose of vaccine [in these young children]. While one case of hemorrhagic stroke and one case of pulmonary embolism were identified after vaccination, chart review found each outcome was unrelated to vaccination as both children had congenital abnormalities. In descriptive analyses, one case of anaphylaxis was found also to be unrelated to vaccination (due to food allergy). Authors of the study expressed confidence in the findings based on the diverse population surveyed, weekly analyses, and a robust capture of outcome and vaccination data. They say the results should provide
reassurance to clinicians, parents, and policymakers.
Related Link
* JAMA Pediatrics: Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years ([link removed]) (5/22/23)
Back to top (#Top)
------------------------------------------------------------
"Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth" published in Pediatrics
In the May 5 issue, Pediatrics published Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth ([link removed]) . The conclusions section appears below.
Messages that focus on trusted parents choosing to vaccinate their children were more effective at promoting parents’ COVID-19 vaccination intentions for their children than alternative messages. These findings have implications for public health messaging and pediatric providers’ communications with parents.
Back to top (#Top)
------------------------------------------------------------
"Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020" published in Pediatrics
In the May 23 issue, Pediatrics published Trends in Reasons for Human Papillomavirus Vaccine Hesitancy: 2010–2020 ([link removed]) . The conclusions section appears below.
Parents who cited vaccine safety as a reason for not intending to vaccinate their adolescent children against HPV increased over time. Findings support efforts to address parental safety concerns surrounding HPV vaccination.
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Moderna offers five-part webinar series High-Risk Populations – Protecting Patients at High Risk of Severe COVID-19 in June
Moderna is offering a free, five-part webinar series High-Risk Populations – Protecting Patients at High-Risk of Severe COVID-19 ([link removed]) in June. This five-part webinar series will discuss the continued risks and consequences of COVID-19 infections in high-risk populations. Each event will focus on a different high-risk population. Courses include:
* TODAY: June 7 at 3:00 p.m. (ET): "Older Adults (65+)"
* June 13 at 1:00 p.m. (ET): "Patients with Chronic Diseases"
* June 15 at 1:00 p.m. (ET): "Immunocompromised Patients"
* June 22 at 1:00 p.m. (ET): "Patients with Cardiovascular Diseases"
* June 28 at 1:30 p.m. (ET): "Patients with Respiratory Diseases"
[link removed]
Registration is required for each event separately.
Register for the free webinars ([link removed]) .
Back to top (#Top)
------------------------------------------------------------
Virtual: Watch June 15–16 National Vaccine Advisory Committee meeting
The National Vaccine Advisory Committee (NVAC) will hold its next meeting June 15–16, starting at 9 a.m. (ET). NVAC will hear presentations on vaccine safety, antimicrobial resistance, pandemic preparedness, and routine vaccination.
Attendance is open to the public on a first-come, first-served basis by registration. Registration is now available online ([link removed]) .
Related Link
* NVAC: ([link removed]) Meeting Information ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Virtual: Watch June 21–23 ACIP meeting. Topics include RSV, polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines.
CDC will convene an extended, 3-day meeting of the Advisory Committee on Immunization Practices ([link removed]) (ACIP), June 21–23, starting at 8 a.m. (ET). ACIP will discuss vaccination recommendations for respiratory syncytial virus (RSV), polio, influenza, pneumococcal, dengue, chikungunya, mpox, meningococcal, and COVID-19 vaccines.
[link removed]
No registration is required to watch webcasts of live ACIP meetings or listen via telephone. Opportunities for public comment are described on the website.
View the agenda ([link removed]) .
Related Links
* ACIP main page ([link removed]) for access to webcast, agendas
* ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp